Novel Biomarkers in Early Detection of Heart Failure: A Narrative Review
- PMID: 38435138
- PMCID: PMC10909379
- DOI: 10.7759/cureus.53445
Novel Biomarkers in Early Detection of Heart Failure: A Narrative Review
Abstract
Heart failure (HF) represents a significant global health challenge, characterized by a variety of symptoms resulting from cardiac dysfunction. This dysfunction often leads to systemic and pulmonary congestion. The pathophysiology of HF is complex, involving stimulation of the sympathetic nervous system, which is insufficiently balanced by the release of natriuretic peptide. This imbalance leads to progressive hypertrophy and dilatation of the heart's chambers, impairing its pumping efficiency and increasing the risk of arrhythmias and conduction disorders. The prevalence of HF is exceptionally high in industrialized nations and is expected to increase owing to an aging population and advancements in diagnostic methods. This study emphasizes the critical role of early diagnosis in reducing morbidity and mortality associated with HF, focusing specifically on the evolving importance of biomarkers in managing this condition. Biomarkers have played a key role in transforming the diagnosis and treatment of HF. Traditional biomarkers such as b-type natriuretic peptide and N-terminal pro-b-type natriuretic peptide have been widely adopted for their cost-effectiveness and ease of access. However, the rise of novel biomarkers such as growth differentiation factor 15 and adrenomedullin has shown promising results, offering superior sensitivity and specificity. These new biomarkers enhance diagnostic accuracy, risk stratification, and prognostic evaluation in HF patients. Despite these advancements, challenges remain, such as limited availability, high costs, and the need for further validation in diverse patient populations. Through a comprehensive literature review across databases such as PubMed, Google Scholar, and the Cochrane Library, this study compiles and analyzes data from 18 relevant studies, offering a detailed understanding of the current state of HF biomarkers. The study examines both traditional and emerging biomarkers such as galectin-3 and soluble suppression of tumorigenicity 2 in HF, exploring their clinical roles and impact on patient outcomes.
Keywords: bnp; cardiac troponin; heart failure; procalcitonin; serum biomarkers.
Copyright © 2024, Kayani et al.
Conflict of interest statement
The authors have declared that no competing interests exist.
Figures
![Figure 1](https://cdn.statically.io/img/www.ncbi.nlm.nih.gov/pmc/articles/instance/10909379/bin/cureus-0016-00000053445-i01.gif)
Similar articles
-
Biomarkers and diagnostics in heart failure.Biochim Biophys Acta. 2013 Dec;1832(12):2442-50. doi: 10.1016/j.bbadis.2012.12.014. Epub 2013 Jan 9. Biochim Biophys Acta. 2013. PMID: 23313577 Review.
-
Biomarkers for the diagnosis and management of heart failure.Heart Fail Rev. 2022 Mar;27(2):625-643. doi: 10.1007/s10741-021-10105-w. Epub 2021 Apr 14. Heart Fail Rev. 2022. PMID: 33852110 Free PMC article. Review.
-
Beyond Natriuretic Peptides: Unveiling the Power of Emerging Biomarkers in Heart Failure.Biomolecules. 2024 Mar 6;14(3):309. doi: 10.3390/biom14030309. Biomolecules. 2024. PMID: 38540729 Free PMC article. Review.
-
Novel heart failure biomarkers: why do we fail to exploit their potential?Crit Rev Clin Lab Sci. 2018 Jun;55(4):246-263. doi: 10.1080/10408363.2018.1460576. Epub 2018 Apr 17. Crit Rev Clin Lab Sci. 2018. PMID: 29663841 Review.
-
Biomarkers and heart disease.Eur Rev Med Pharmacol Sci. 2014 Oct;18(19):2927-35. Eur Rev Med Pharmacol Sci. 2014. PMID: 25339488 Review.
Cited by
-
A Case of Acute Respiratory Distress Syndrome Following Non-thoracic Trauma in a Patient With Idiopathic Pulmonary Fibrosis.Cureus. 2024 Jun 29;16(6):e63467. doi: 10.7759/cureus.63467. eCollection 2024 Jun. Cureus. 2024. PMID: 39077261 Free PMC article.
References
-
- Biomarkers in heart failure: the past, current and future. Sarhene M, Wang Y, Wei J, et al. Heart Fail Rev. 2019;24:867–903. - PubMed
-
- Universal definition and classification of heart failure: a report of the Heart Failure Society of America, Heart Failure Association of the European Society of Cardiology, Japanese Heart Failure Society and Writing Committee of the Universal Definition of Heart Failure. Bozkurt B, Coats AJ, Tsutsui H, et al. J Card Fail. 2021;27:387–413.
-
- Biomarkers and surrogate endpoints: preferred definitions and conceptual framework. Clin Pharmacol Ther. 2001;69:89–95. - PubMed
Publication types
LinkOut - more resources
Full Text Sources
Research Materials
Miscellaneous